Lipaglyn Tablet
Marketer
Zydus Cadila
Salt Composition
Saroglitazar (4mg)
Overview Lipaglyn Tablet
Lipaglyn tablets treat Nonalcoholic Steatohepatitis (NASH) in patients without cirrhosis, Nonalcoholic Fatty Liver Disease (NAFLD) complicated by obesity, type 2 diabetes, dyslipidemia, or metabolic syndrome, and high cholesterol in diabetic patients (diabetic dyslipidemia). For optimal results, take Lipaglyn daily at the same time, with or without food, and only discontinue use as directed by your physician. Adherence to your prescribed diet and exercise plan is crucial. Maintaining a healthy weight through lifestyle changes significantly contributes to liver health. Common, typically mild, side effects include gas, indigestion, bloating, fever, and fatigue. Report persistent or concerning side effects to your doctor. Prior to starting Lipaglyn, inform your doctor of any history of kidney, heart, or pancreatic disease, excessive alcohol consumption, or pregnancy/breastfeeding. Disclose all other medications you're using, as interactions may occur. Reduce alcohol intake while using Lipaglyn to protect your liver. Regular monitoring of liver and kidney function, as well as blood glucose levels, may be necessary to assess treatment efficacy.
Primary Ingredients of Lipaglyn Tablet
No text provided. Please provide the text you wish me to rephrase.
Uses of Lipaglyn Tablet
Managing non-cirrhotic, non-alcoholic steatohepatitis; addressing non-alcoholic fatty liver disease; and therapeutic intervention for diabetic dyslipidemia.
Major Benefits of Lipaglyn Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Lipaglyn Tablet whole; avoid chewing, crushing, or breaking it. While it can be taken with or without food, consistency is key—take it at the same time each day.
Common Side effects of Lipaglyn Tablet:
- Flatulence
- Indigestion
- Abdominal distension
- Weakness
- Increased body temperature
How to use Lipaglyn Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Lipaglyn Tablet whole; avoid chewing, crushing, or breaking it. This medication can be taken with or without food, although consistent timing is recommended.
How Lipaglyn Tablet works:
Lipaglyn tablets utilize Saroglitazar, a dual-acting peroxisome proliferator-activated receptor (PPAR) antagonist, to help control elevated cholesterol, particularly triglycerides, and blood glucose in individuals with type 2 diabetes. This is achieved through a novel mechanism that decreases triglyceride production and release (a blood lipid). Concurrently, it enhances the body's insulin response, improving insulin effectiveness and consequently reducing blood sugar.
SAFETY ADVICE
AlcoholUNSAFE
Avoid alcohol while taking Lipaglyn Tablets.
PregnancyCONSULT YOUR DOCTOR
Use of Lipaglyn Tablets during pregnancy may pose risks. While human research is scant, animal studies indicate potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.
Breast feedingCAUTION
The use of Lipaglyn Tablets while breastfeeding requires careful consideration. Mothers should discontinue breastfeeding for the duration of their treatment and until the medication is fully cleared from their system.
DrivingSAFE
Driving ability is typically unaffected by Lipaglyn Tablet.
KidneyCONSULT YOUR DOCTOR
Insufficient data exists regarding Lipaglyn Tablet use in individuals with renal impairment. Physician consultation is advised.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding Lipaglyn Tablet use in individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Lipaglyn Tablet :
Omit a dose? Take it immediately if you remember. However, if your next dose is imminent, forgo the missed one and continue with your regular schedule. Never take a double dose.
Facts to Know About Lipaglyn Tablet
| Label | Value |
|---|---|
| Chemical Type | Phenylpyrrole Analog |
| Developing Habits | No. |
| Treatment Category | Diabetes Treatment |
| Actions | PPARα/γ dual agonist |
3,018 People bought this recently